Related Articles
Systemic or topical application of plasminogen activator inhibitor with extended half-life (VLHL PAI-1) reduces bleeding time and total blood loss
Comparison between the clot-protecting activity of a mutant plasminogen activator inhibitor-1 with a very long half-life and 6-aminocaproic acid
Remarkable extension of PAI-1 half-life surprisingly brings no changes to its structure
VLHL plasminogen activator inhibitor spontaneously reactivates from the latent to active form
Challenging delivery of VLHL NS plasminogen activator inhibitor-1 by osmotic pumps in diabetic mouse: A case report